- Home
- AMAL vs ORKA Comparison
AMAL vs ORKA Comparison
Compare AMAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | ORKA |
|---|---|---|
| Founded | 1923 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.6B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | AMAL | ORKA |
|---|---|---|
| Price | $38.09 | $39.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $33.50 | ★ $52.70 |
| AVG Volume (30 Days) | 132.4K | ★ 293.7K |
| Earning Date | 04-22-2026 | 01-01-0001 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.18 | N/A |
| Revenue Next Year | $6.55 | N/A |
| P/E Ratio | $11.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.13 | $5.49 |
| 52 Week High | $42.66 | $36.53 |
Technical Indicators
Market Signals| Indicator | AMAL | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 66.53 |
| Support Level | $29.03 | $26.02 |
| Resistance Level | $39.34 | N/A |
| Average True Range (ATR) | 1.25 | 2.55 |
| MACD | -0.29 | 0.25 |
| Stochastic Oscillator | 36.41 | 83.94 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.